protection, anticancer and immunological disease 5) as well as ginsenoside. 6) Many preparations of TPNS were used in clinic including tablet, drop pill and injection. Xuesaitong injection was one of these preparations which only consisted of TPNS. 7) As a kind of typical multiple constituent and multiple actions traditional Chinese medicine (TCM), it was very difficult to evaluate the pharmacokinetic profiles of TPNS in rats or human. Only several literatures reported recent years for the pharmacokinetic study of TPNS (powder or liposomes) according to the evaluation of ginsenoside Rg1 and Rb1 after oral, intravenous and pulmonary instillation administration TPNS in rats. [8] [9] [10] It was not perfect for the pharmacokinetic evaluation of TPNS when panax notoginsenoside R1, a kind of typical constituent in San-Chi was missed.
The development of analytical technique gives us a possibility for the trace determination of constitutent of TCM in bio-sample. In this contribution, a developed and validated LC-ESI-MS method was employed for the simultaneous determination of panax notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 in rat plasma. A reasonable and general pharmacokinetic profile of TPNS in rats was obtained according to the evaluation of absolute bioavailability and pharmacokinetic profiles of the consitutents mentioned above. Mass Spectrometry Detection The LC-MS2010 A series system (Shimadzu, Japan) was equipped with a binary pump, on-line vacuum degasser, autosampler, column compartment, mass spectrometry detector of electrospray interface, and LCMS Solution Version 2.04 S. The ESI ion source was set in the negative ion polarity mode for acquiring all mass spectrometry data. Assaying of Panax Notoginsenoside R1, Ginsenoside Rg1, Rd, Re and Rb1 in TPNS and Xuesaitong (TPNS) Injection The calibration curves of all analytes were prepared over the concentration of 10.0-160.0 mg/ml in methanol. TPNS and Xuesaitong (TPNS) injection were prepared at the concentration of 0.5 mg/ml (nϭ6). All procedures were performed on LC 2010 system (Shimadzu, Japan) with UV detector at 203 nm wavelength. The stabilities of QC sample at the time of 0, 2, 4, 6, 12 and 24 h and accuracy and repeat were investigated during our analytical process.
MATERIALS AND METHODS

Chemicals and Reagents
Pharmacokinetic Protocols of TPNS in Rats Twelve Sprague-Dawley rats (male and female, 180-220 g) were purchased from experimental animal center (China Pharmaceutical University) and used in the study after a 1-week acclimatization period. After overnight fasting, TPNS powder and Xuesaitong (TPNS) injection were administered via orally or intravenously at the dosage of 300.0 and 10.0 mg/kg, respectively to each group of rats for the plasma concentration-time course study. Blood samples were collected in heparinized tubes at 0, 0.08, 0.25, 0. Sample Preparation Extraction and cleanup of rat plasma samples were carried out by liquid-liquid extraction (LLE) according to the following procedure. To 100.0 ml aliquot of rat plasma sample, 10.0 ml aliquot of internal standard (500.0 ng/ml digoxin solution) was added. The sample was briefly mixed for about 30 s and n-butanol (1.0 ml) was added. The mixture was vortex-mixed for approximately 3.0 min. After centrifugation at 3000ϫg for 5 min, 0.8 ml upper organic layer was removed to clean Eppendorf tube and evaporated to dryness in a Speed Vacplus Model vacuum drier. Each residue sample was reconstituted with 100.0 ml methanol, vortex-mixed for 2 min and centrifuged at 15000ϫ g for 10 min, and 10.0 ml of supernatant was injected onto the HPLC-MS system.
Data Analysis Content assaying of all analytes was performed according to the calibration curves on 2010 HPLC system. Determination of all analytes in rat plasma was processed on LC/ESI/MS system. The peak areas of all analytes and the internal standard were measured. The peak area ratios of analytes relative to that of the internal standard were calculated and used for construction of the standard curves. These peak area ratios were plotted against the spiked concentration of all standard analytes. Least-square linear regression was then used to determine the linearity of the curves and calculate the slope, intercept, and correlation coefficient of the line for each of the analytes. The concentration of each analytes was calculated based on the standard curve. All data is represented as meanϮS.D.
RESULTS
Content Assaying
The content of panax notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 in TPNS and Xuesaitong (TPNS) injection was determined successfully on the condition mentioned above. All analytes in TPNS powder and Xuesaitong (TPNS) injection were stable during the analytical times of 0, 2, 4, 6, 12 and 24 h. The RSD% of accuracy and repeat for all analytes was less than 11.3%. Assaying results were showed in Table 1 . Content of all analytes displayed no statistic difference between TPNS powder and Xuesaitong (TPNS) injection.
Method Validation The linear regression analysis of analytes were constructed by plotting the peak area ratios of analytes to the internal standard (y) versus analytes concentration spiked plasma samples (x). Five sets of calibration curves were established. The mean regression equation of these curves was calculated as follows: yϭ0.0028xϪ0.0090 (R 2 ϭ0.9994) for panax notoginsenoside R1, yϭ0.0025xϪ 0.9990) for ginsenoside Rb1, which showed good linear relationships between the peak area and the concentration. The low limit of quantification (LLOQ) of R1, Rg1, Rd, Re and Rb1 were of 3.03, 4.00, 4.00, 4.00 and 2.77 ng/ml in rat plasma. The recoveries of all analytes were of 67.5-94.2%.
Intra-and inter-day assay precision (CV%) of panax notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 were at the range of 1.82-11.46% over the concentration of 12.11, 96.88 and 387.5 ng/ml for panax notoginsenoside R1, 16.02, 128.13 and 512.52 ng/ml for ginsenoside Rg1, Rd and Re, 11.09, 88.75 and 355.0 ng/ml for ginsenoside Rb1.
The mean accuracy from the spiked concentration was from 97.52 to 102.54% for panax notoginsenoside R1, 97.62 to 100.54% for ginsenoside Rg1, 96.88 to 100.17% for ginsenoside Rd, 97.85 to 101.14% for ginsenoside Re, 97.28 to 100.81% for ginsenoside Rb1 at the concentration of QC sample under the condition of 12 h in ambient temperature, 4°C 12 h in sample pool, Ϫ20°C for four weeks and Ϫ20°C for three thaw-freeze cycles.
Chromatograms and Pharmacokinetic Parameters Typical chromatograms of all analytes and digoxin (IS) were obtained and shown in Fig. 2 . The mean plasma concentration-time profiles of panax notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 after oral administration of TPNS powder (300 mg/kg) or intravenous administration of Xuesaitong (TPNS) injection (10 mg/kg) were obtained in Figs. 3 and 4 , respectively. Pharmacokinetic parameters were estimated using the DAS pharmacokinetic software (1.0 version). Maximum concentration (C max ) and time to maximum concentra- Tables  2 and 3 respectively. The absolute bioavailability of panax notoginsenoside R1, ginsenside Rg1, Rd, Re and Rb1 were of 9.29%, 6.06%, 2.36%, 7.06% and 1.18%, respectively.
DISCUSSIONS
After preliminary testing, LC/ESI/MS method was developed and validated for the simultaneous determination of panax notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 in rat plasma instead of TLC, 11) HPLC 10, [12] [13] [14] and LC/MS/ MS 15, 16) for their shortcoming of poor sensitivity, specificity, selectivity and expensive cost. There was no any endogenous matrix interference with all analytes and all chromatographic run time were within 10.0 min.
Many researchers focused on total panax notoginsenoside (TPNS) because of its multiple constituents and important role in clinic during the past several decades. However, no any further more progress obtained on the pharmacokinetic evaluation of TPNS because of its multiple constituents. It was very difficult for us to choose suitable constituents to evaluate the pharmacokinetics profiles of TPNS because of its multiple constituents and the limit of analytical technology. Rg1 and Rb1 were often considered for high content in TPNS. Odani research group reported the ADME profiles of ginsenoside Rg1 and Rb1 isolated from panax ginseng in rats in 1980s. 11, 17) Pharmacokinetic profiles of TPNS reported recent years according to the pharmacokinetic evaluation of ginsenoside Rg1 and Rb1 [9] [10] [11] [12] in rat. However, it was a kind of jug-handled research only focus on Rg1 and Rb1. TPNS is a kind of typical multiple constituent TCM widely used in oriental countries and it is necessary for the systematic pharmacokinetic evaluation of TPNS. According to the content assaying of TPNS in this study ( Table 1 ) we know that panax notoginenoside R1, ginsenoside Rg1, Rd, Re and Rb1 are the main constituents of TPNS. The total percentage of these constituents is more than 78.53% in TPNS. It is reasonable and necessary for the pharmacokinetic study of panax notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 when the pharmacokinetic profile of TPNS being evaluated in rats. In this study, LC/ESI/MS method was successfully employed for the pharmacokinetic evaluation of TPNS in rats. Main pharmacokinetic parameters of these constituents mentioned above were obtained by DAS pharmacokinetic software recommendation from Chinese Pharmacological Association. From the results we know that after oral administration of TPNS powder in rats, panax notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 reached peak concentration in plasma rapidly within about 0.75 h which hint their absorption were quickly. Maximum concentration of R1, Rg1, Rd, Re and Rb1 in rat plasma were between 1.51 to 6.42 mg/ml means their poor absorption. T 1/2 was changed from 1.01 to 20.15 h for 5 analytes in rat plasma. After intravenous administration of Xuesaitong (TPNS) injection in rats, most of constituents were cleared quickly except ginsenoside Rd and Rb1. T 1/2 was changed from 0.72 to 22.16 h, V d from 6.20 to 27.65 l/kg and CL from 0.12 to 10.72 l/h/kg for all analytes. Absolute bioavailability study suggested that all ginsenosides in TPNS were poorly absorbed by rats. The reasons maybe included that these saponins were destroyed in gastrointestinal tract, metabolized by intestinal microflora 18) and excreted from bile or urine. The variability of T 1/2 , V d , CL and AUC for all analytes maybe related to the binding ratio of plasma protein (ginsenoside Rg1 was of low ratio whereas Rb1 was high 17) ). 850 Vol. 30, No. 5 
